We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Neurofilament Light Chain: A High-Performance Biomarker for Differentiating bvFTD from Primary Psychiatric Disorders

MedXY Editorial Team•Feb 14, 2026•Neurology
biomarkersfrontotemporal dementia

Highlights

  • NfL levels in both CSF and blood are significantly elevated in patients with behavioral variant frontotemporal dementia (bvFTD) compared to those with primary psychiatric disorders.
  • Blood-based NfL assays demonstrated high diagnostic performance, with AUCs reaching up to 0.98, suggesting a minimally invasive alternative to lumbar punctures.
  • The biomarker provides critical objective data to resolve diagnostic uncertainty in middle-aged patients presenting with complex behavioral and personality changes.

The Diagnostic Dilemma in Neuropsychiatry

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unlocking the Potential of Novel Biomarkers for Acute Kidney Injury in the Critically Ill: A Comprehensive Evidence MappingThis article reviews over 1100 studies on novel biomarkers for acute kidney injury (AKI) in critically ill patients, highlighting their predictive, diagnostic, and management roles while identifying gaps for future clinical implementation.Sep 18, 2026Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian CohortHost blood transcriptomic signatures effectively monitor treatment response and predict recurrence and mortality in drug-susceptible pulmonary tuberculosis, meeting WHO benchmarks and enabling personalized therapy strategies.Sep 17, 2026Advancing Fetal Death Detection: Identification of Novel Maternal Plasma Biomarkers Through Large-Scale Proteomic ProfilingLarge-scale proteomic analysis identifies novel maternal plasma protein biomarkers that improve detection of fetal death beyond established markers, highlighting both shared and unique pathological pathways with preeclampsia.Sep 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Decoding Neuroendocrine Carcinomas: Proteomic Insights Define Subtypes, Biomarkers, and Therapeutic Opportunities
Comprehensive proteomic and phosphoproteomic profiling of 267 neuroendocrine carcinomas across multiple tissues reveals distinct molecular subtypes, biomarkers, and a novel NAD+ metabolic vulnerability, advancing personalized precision medi
Aug 28, 2026
Plasma POMC as a Predictive Biomarker for Silent Corticotroph Adenomas in Non-Functioning Pituitary TumorsElevated plasma pro-opiomelanocortin (POMC) levels accurately predict silent corticotroph adenomas (SCAs) among clinically non-functioning pituitary adenomas, offering a promising tool for diagnosis and monitoring.Aug 27, 2026
Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-ScoresSerum neurofilament light chain (sNfL) z-score dynamics enhance monitoring of treatment response in relapsing multiple sclerosis (RMS), providing complementary predictive value for disease activity beyond conventional clinical and MRI assesAug 21, 2026